secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0000950170-24-139962
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Assembly Biosciences reports interim Phase 1b data for ABI-4334 with 2.9 log10 IU/mL mean HBV DNA reduction
--------------------------------------------------------------------------------

- ABI-4334 was well-tolerated with favorable safety profile; no serious adverse events or discontinuations in either cohort.
- In 150 mg dose cohort, mean HBV DNA declined 2.9 log10 IU/mL and mean HBV RNA declined 2.5 log10 U/mL over 28 days.
- Half-life supports once-daily oral dosing; Cmin multiples above EC50 for antiviral activity and cccDNA inhibition.
- Enrollment ongoing for 400 mg cohort, expected final cohort; data anticipated in first half of 2025.
- Gilead Sciences has opt-in rights to further develop and commercialize ABI-4334 after completion of Phase 1b study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024139962/0000950170-24-139962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024139962/asmb-20241226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-139962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer